Top member reports
Consensus community valuation
Contributing Members
Sort by:
Recent
Create your free Strawman account to view member valuations
##RAP Opportunity
Last edited 2 months ago

Anyone following RAP. They have recently partnered with Coviu, who are in their early seed rounds. One might assume some combined market strength once Coviu IPO's. Risks may be consumers' unwillingness to take up telehealth and likewise resistance from doctors who are quite comfortable (excluding further lockdowns) in the face to face model they are used to. Any thoughts?

Read More
#ASX Announcements
Added 3 months ago

ResApp Health grants cough counting SDK licence to AstraZeneca Japan for asthma patient support program

  • Second licensing agreement secured with AstraZeneca’s Japanese subsidiary for ResApp technology
  • Extends use of cough counting from clinical research in lung cancer to a patient support program for asthma
  • First time ResApp’s cough counting technology is being used outside of a clinical trial setting
  • ResApp’s cough counting software development kit (SDK) to be integrated into AstraZeneca’s Asthma Monitoring App to support patients
  • Cough counting SDK designed to measure frequency of patient coughs over extended periods – cough frequency can provide insight into the progression and management of respiratory disease
  • Agreement is significant validation of ResApp’s technology from a leading global pharmaceutical company

View Attachment

Read More
#ASX Announcement 10/2/21
Added 4 months ago

Pre-Submission package lodged with the US FDA

Brisbane, Australia, 10 February 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA) and requested a meeting with the agency to progress the potential clearance of a prescription-only software as a medical device application to detect lower respiratory tract illness in children and adults.

View Attachment

Read More